NANEXA AB: Positive clinical data balanced by strategic uncertainty about NEX-22 roadmap

Analys, Research

Nanexa presented strong validation of its PharmaShell technology during the first half of 2025, with Phase I data showing once-monthly...

Read More

PROLIGHT: Fully subscribed rights issue strengthens Psyros case ahead of commercial partnerships

Analys, Research

Prolight announced that its rights issue was fully subscribed, eliminating near-term financing risk and securing the capital needed to...

Read More

CRUNCHFISH: Breakthrough integration sets stage for commercial expansion

Analys, Research

Crunchfish’s new go-to-market strategy for offline payments, splitting the solution into terminals for payment networks and wallets for...

Read More

For new research on growth stocks, sign up to our newsletter